The new M&A deals, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New M&A deals, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Deal Trends
See who's moving and how much in your market
No credit card required Weekly M&A digest
Elaris acquires Matrivax for CDI vaccine development
PRIVATEMay 05, 2026•about 1 month ago
Acquiring Company
Elaris FlexCo
Acquired Company
WORQ
AustriaMalaysia
Description
Elaris FlexCo has announced the acquisition of Matrivax Research & Development Corporation to strengthen its efforts in developing a differentiated vaccine against Clostridioides difficile infection. The asset purchase includes key intellectual property and materials to advance this critical approach. As part of the agreement, Matrivax will receive an equity stake in Elaris and royalties from future product sales.
Company Information
Company
Elaris FlexCo
Location
Austria
About
Elaris is a biotechnology company developing next-generation bacterial vaccines to protect aging and medically vulnerable populations from serious bacterial diseases. Its lead program targets Clostridioides difficile, a severe hospital-acquired infection. Elaris aims to reduce hospitalizations and the burden of antimicrobial resistance through preventive solutions.
Predictive Intelligence
Strategic
ML-powered predictions for Elaris FlexCo's next move
Austria
Malaysia